Stocks of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded higher last session on Wall Street, up 1.17% to $56.93.
According to the data, Integra LifeSciences Holdings Corporation (NASDAQ:IART) has 14 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $75.00 and a low of $50.00, we find $58.00. Given the previous closing price of $56.27, this indicates a potential upside of 3.07 percent. IART stock price is now 2.96% away from the 50-day moving average and 5.24% away from the 200-day moving average. The market capitalization of the company currently stands at $4.67B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 9 analysts have issued a hold rating and 3 have given it a buy rating. Brokers who have rated the stock have averaged $58.40 as their price target over the next twelve months.
On July 25, 2022, Morgan Stanley recently initiated its ‘Equal-Weight’ rating on the stock quoting a target price of $59, while ‘Truist’ rates the stock as ‘Hold’.
In other news, Mosebrook Jeffrey, SVP, Fin & Princ Acct Officer sold 279 shares of the company’s stock on Dec 08. The stock was sold for $15,684 at an average price of $56.22. Upon completion of the transaction, the SVP, Fin & Princ Acct Officer now directly owns 8,552 shares in the company, valued at $0.49 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 10, Executive Vice President &CHRO Evoli Lisa sold 1,165 shares of the business’s stock. A total of $65,020 was realized by selling the stock at an average price of $55.81. This leaves the insider owning 17,997 shares of the company worth $1.02 million. Insiders disposed of 298,230 shares of company stock worth roughly $16.98 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IART stock. A new stake in Integra LifeSciences Holdings Corporation shares was purchased by BANK OF NOVA SCOTIA during the first quarter worth $14,591,000. BALYASNY ASSET MANAGEMENT LLC invested $12,073,000 in shares of IART during the first quarter. In the first quarter, MAGNETAR FINANCIAL LLC acquired a new stake in Integra LifeSciences Holdings Corporation valued at approximately $3,344,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in IART for approximately $2,863,000. HOLOCENE ADVISORS, LP purchased a new stake in IART valued at around $2,602,000 in the second quarter. In total, there are 384 active investors with 91.60% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $56.27 for Integra LifeSciences Holdings Corporation (NASDAQ: IART). During the past 12 months, Integra LifeSciences Holdings Corporation has had a low of $40.67 and a high of $68.29. As of last week, the company has a debt-to-equity ratio of 0.90, a current ratio of 3.90, and a quick ratio of 2.90. The fifty day moving average price for IART is $55.44 and a two-hundred day moving average price translates $54.06 for the stock.
The latest earnings results from Integra LifeSciences Holdings Corporation (NASDAQ: IART) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at $0.86, beating analysts’ expectations of $0.72 by 0.14. This compares to $0.51 EPS in the same period last year. The net profit margin was 11.10% and return on equity was 10.40% for IART. The company reported revenue of $385.19 million for the quarter, compared to $386.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.43 percent. For the current quarter, analysts expect IART to generate $397.3M in revenue.
Integra LifeSciences Holdings Corporation(IART) Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
